Life or death

References

• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:38 - 44
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402 - 412
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749 - 758
   PubMed Web of Science ®Google Scholar
• Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008; 134:451 - 460
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle 2009; 8:3777 - 3781
   PubMed Web of Science ®Google Scholar
• Steelman LS, McCubrey JA. Intriguing novel abilities of Nutlin-3A: induction of cellular quiescence as opposed to cellular senescence—implications for chemotherapy. Cell Cycle 2009; 8:3634 - 3635
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660 - 9664
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344 - 352
   PubMedGoogle Scholar
• Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, et al. DNA binding cooperativity of p53 modulates the decision between cell cycle arrest and apoptosis. Mol Cell 2010; 38:356 - 368
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656 - 660
   PubMed Web of Science ®Google Scholar
• Meyer M, Rubsamen D, Slany R, Illmer T, Stabla K, Roth P, et al. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 2009; 4:7768
   Web of Science ®Google Scholar
• Aylon Y, Oren M. Living with p53, dying of p53. Cell 2007; 130:597 - 600
   PubMed Web of Science ®Google Scholar
• Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008; 9:702 - 712
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458:1127 - 1130
   PubMed Web of Science ®Google Scholar
• Morselli E, Galluzzi L, Kepp O, Kroemer G. Nutlin kills cancer cells via mitochondrial p53. Cell Cycle 2009; 8:1647 - 1648
   PubMed Web of Science ®Google Scholar
• Vaseva AV, Marchenko ND, Moll UM. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 2009; 8:1711 - 1719
   PubMed Web of Science ®Google Scholar
• Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004; 116:499 - 509
   PubMed Web of Science ®Google Scholar
• Hearnes JM, Mays DJ, Schavolt KL, Tang L, Jiang X, Pietenpol JA. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol 2005; 25:10148 - 10158
   PubMed Web of Science ®Google Scholar
• Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, et al. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 2008; 36:3639 - 3654
   PubMed Web of Science ®Google Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207 - 219
   PubMed Web of Science ®Google Scholar
• Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992; 12:2866 - 2871
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45 - 49
   PubMed Web of Science ®Google Scholar
• Das S, Boswell SA, Aaronson SA, Lee SW. p53 promoter selection: choosing between life and death. Cell Cycle 2008; 7:154 - 157
   PubMed Web of Science ®Google Scholar
• Blattner C. Regulation of p53: the next generation. Cell Cycle 2008; 7:3149 - 3153
   PubMed Web of Science ®Google Scholar
• Georges SA, Chau BN, Braun CJ, Zhang X, Dobbelstein M. Cell cycle arrest or apoptosis by p53: are microRNAs-192/215 and -34 making the decision?. Cell Cycle 2009; 8:680 - 681
   PubMed Web of Science ®Google Scholar
• Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer 2006; 6:217 - 226
   PubMed Web of Science ®Google Scholar
• Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781 - 794
   PubMed Web of Science ®Google Scholar
• Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33:162 - 167
   PubMed Web of Science ®Google Scholar
• Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006; 38:1133 - 1141
   PubMed Web of Science ®Google Scholar
• Perez-Sanchez C, Budhram-Mahadeo VS, Latchman DS. Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter. Nucleic Acids Res 2002; 30:4872 - 4880
   PubMed Web of Science ®Google Scholar
• Budhram-Mahadeo VS, Bowen S, Lee S, Perez-Sanchez C, Ensor E, Morris PJ, et al. Brn-3b enhances the proapoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression. Nucleic Acids Res 2006; 34:6640 - 6652
   PubMed Web of Science ®Google Scholar
• Hudson CD, Morris PJ, Latchman DS, Budhram-Mahadeo VS. Brn-3a transcription factor blocks p53-mediated activation of proapoptotic target genes Noxa and Bax in vitro and in vivo to determine cell fate. J Biol Chem 2005; 280:11851 - 11858
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Gromley A, Sherr CJ. Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage. Mol Cell Biol 2006; 26:502 - 512
   PubMed Web of Science ®Google Scholar
• Sharma S, Dimasi D, Higginson K, Della NG. RZF, a zinc-finger protein in the photoreceptors of human retina. Gene 2004; 342:219 - 229
   PubMed Web of Science ®Google Scholar
• Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, et al. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 2007; 130:624 - 637
   PubMed Web of Science ®Google Scholar
• Miao L, Song Z, Jin L, Zhu YM, Wen LP, Wu M. ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation. Oncogene 2010; 29:711 - 722
   PubMed Web of Science ®Google Scholar
• Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002; 10:509 - 521
   PubMed Web of Science ®Google Scholar
• D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002; 4:11 - 19
   PubMed Web of Science ®Google Scholar
• Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F, et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 2007; 25:739 - 750
   PubMed Web of Science ®Google Scholar
• Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007; 25:725 - 738
   PubMed Web of Science ®Google Scholar
• Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4:1 - 10
   PubMed Web of Science ®Google Scholar
• Perfettini JL, Castedo M, Nardacci R, Ciccosanti F, Boya P, Roumier T, et al. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med 2005; 201:279 - 289
   PubMed Web of Science ®Google Scholar
• Yoshida K, Liu H, Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 2006; 281:5734 - 5740
   PubMed Web of Science ®Google Scholar
• Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008; 283:3979 - 3987
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis and its regulation by Ser46-phosphorylated p53. Cell 2000; 102:849 - 862
   PubMed Web of Science ®Google Scholar
• Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X, et al. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 2007; 14:912 - 920
   PubMed Web of Science ®Google Scholar
• Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24:841 - 851
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell cycle arrest and apoptosis. Mol Cell 2006; 24:827 - 839
   PubMed Web of Science ®Google Scholar
• Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 2006; 173:533 - 544
   PubMed Web of Science ®Google Scholar
• Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 2006; 26:6859 - 6869
   PubMed Web of Science ®Google Scholar
• Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127:775 - 788
   PubMed Web of Science ®Google Scholar
• Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B, et al. Arginine methylation regulates the p53 response. Nat Cell Biol 2008; 10:1431 - 1439
   PubMed Web of Science ®Google Scholar
• Durant ST, Cho EC, La Thangue NB. p53 methylation—the Argument is clear. Cell Cycle 2009; 8:801 - 802
   PubMed Web of Science ®Google Scholar
• Dehner A, Klein C, Hansen S, Muller L, Buchner J, Schwaiger M, et al. Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl 2005; 44:5247 - 5251
   PubMed Web of Science ®Google Scholar
• Madhumalar A, Jun LH, Lane DP, Verma CS. Dimerization of the core domain of the p53 family: a computational study. Cell Cycle 2009; 8:137 - 148
   PubMed Web of Science ®Google Scholar
• Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K, et al. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem 2001; 276:49020 - 49027
   PubMed Web of Science ®Google Scholar
• Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006; 22:741 - 753
   PubMed Web of Science ®Google Scholar
• Ho WC, Fitzgerald MX, Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J Biol Chem 2006; 281:20494 - 20502
   PubMed Web of Science ®Google Scholar
• Tidow H, Melero R, Mylonas E, Freund SM, Grossmann JG, Carazo JM, et al. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 2007; 104:12324 - 12329
   PubMed Web of Science ®Google Scholar
• Hager GL, McNally JG, Misteli T. Transcription dynamics. Mol Cell 2009; 35:741 - 753
   PubMed Web of Science ®Google Scholar
• Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005; 6:542 - 554
   PubMed Web of Science ®Google Scholar
• Misteli T. Beyond the sequence: cellular organization of genome function. Cell 2007; 128:787 - 800
   PubMed Web of Science ®Google Scholar
• Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010; 2:935
   PubMed Web of Science ®Google Scholar
• An W, Kim J, Roeder RG. Ordered cooperative functions of PRMT1, p300 and CARM1 in transcriptional activation by p53. Cell 2004; 117:735 - 748
   PubMed Web of Science ®Google Scholar
• Karpova TS, Kim MJ, Spriet C, Nalley K, Stasevich TJ, Kherrouche Z, et al. Concurrent fast and slow cycling of a transcriptional activator at an endogenous promoter. Science 2008; 319:466 - 469
   PubMed Web of Science ®Google Scholar
• McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 2000; 287:1262 - 1265
   PubMed Web of Science ®Google Scholar
• Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, et al. Estrogen receptor-alpha directs ordered, cyclical and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115:751 - 763
   PubMed Web of Science ®Google Scholar
• Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10:2438 - 2451
   PubMed Web of Science ®Google Scholar
• Horvath MM, Wang X, Resnick MA, Bell DA. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet 2007; 3:127
   Web of Science ®Google Scholar
• Ma B, Pan Y, Zheng J, Levine AJ, Nussinov R. Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets. Nucleic Acids Res 2007; 35:2986 - 3001
   PubMed Web of Science ®Google Scholar
• Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci USA 1992; 89:6413 - 6417
   PubMed Web of Science ®Google Scholar
• Sauer M, Bretz AC, Beinoraviciute-Kellner R, Beitzinger M, Burek C, Rosenwald A, et al. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Nucleic Acids Res 2008; 36:1900 - 1912
   PubMed Web of Science ®Google Scholar